Best Longevity Supplements, Rated by Evidence (2026)

Search “longevity supplements” and you will find confident lists promising to slow aging, reverse it, or add years to your life. Almost none of that confidence is earned. So before we grade anything, here is the frame we hold every product to — and it is an uncomfortable one for the supplement industry.

The honest starting point: zero human-lifespan RCTs exist

There is not a single randomized controlled trial showing that any supplement makes humans live longer. Not one. The reason is structural, not lazy: a trial that randomizes people to a pill and follows them until enough have died to detect a lifespan difference would take decades and tens of thousands of participants, and nobody has run it. What we have instead is three weaker tiers of evidence, and the entire longevity-supplement market blurs them together on purpose:

• •Mechanism — “this molecule activates autophagy / sirtuins / AMPK in a dish.” Interesting, proves nothing about you.
• •Animal lifespan data — “it extended lifespan in mice/worms/flies.” Genuinely meaningful for biology, but most compounds that extend rodent lifespan do nothing measurable in humans, and dosing rarely translates.
• •Human biomarker or outcome data — “it raised NAD+,” or, much more rarely, “it reduced a hard clinical event.” This is the only tier that should move your decision, and it is the thinnest.

The biology underneath the hype is real: aging has well-described hallmarks — things like genomic instability, mitochondrial dysfunction, cellular senescence, and declining nutrient-sensing — and supplements are pitched as nudging one or more of them¹. But “plausibly touches a hallmark of aging” is a mechanism claim, not proof that swallowing it helps a person age better. Throughout this guide we keep mechanism and proof in separate boxes. We also keep one regulatory fact in view: these are supplements, not drugs — they are not FDA-approved to treat or prevent any disease, manufacturing quality varies, and the label claims are largely unpoliced. For the bigger picture of what is and isn't established in this field, see our pillar on what longevity medicine can actually prove.

How we grade

Each supplement below gets a tier based only on human evidence:

• •🟢 Reasonable — there is real human outcome or strong biomarker evidence, usually in a specific group (e.g. correcting a deficiency, or a hard-endpoint trial). Not “anti-aging proven,” but a defensible reason to take it.
• •🟡 Speculative — mechanism plus animal data plus thin or surrogate-only human data. Might do something; the longevity claim is unproven.
• •🔴 Hype-led — the marketing vastly outruns the human evidence, which is mostly preclinical or null.

No grade here is influenced by any commercial relationship. This is the same evidence-first rubric we apply to clinics in how we grade longevity providers.

NMN and NR (NAD+ boosters) — 🟡 Speculative

NAD+ is a coenzyme central to energy metabolism and DNA repair, and it falls with age — which is the entire mechanistic case for the NAD+ precursors nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR)². The mechanism is legitimate and the in-vivo preclinical evidence for NAD+ restoration is among the better-developed in the field².

Here is the gap. In humans, the strongest finding is simply that these compounds raise NAD+ levels. Nicotinamide riboside is orally bioavailable and reliably elevates blood NAD+ in people³; a controlled trial in healthy middle-aged and older adults confirmed chronic NR is well-tolerated and boosts NAD+⁴. NMN behaves similarly — a randomized trial in healthy middle-aged adults found it safely raised NAD+⁵. What none of these trials show is a downstream outcome: not longer life, not reversed aging, not even consistent improvements in strength, metabolism, or biological age. Raising a biomarker is a prerequisite for benefit, not benefit itself. We go deeper into where the NAD+ story holds and breaks in NAD+ for longevity: what the trials actually show and do NAD+ peptides work?. Verdict: plausible, well-tolerated, NAD+-raising — but the longevity payoff is unproven.

Spermidine — 🟡 Speculative

Spermidine is a polyamine (found in wheat germ, aged cheese, soy) that triggers autophagy, the cellular-recycling process whose decline is a hallmark of aging — making it one of the more biologically interesting longevity candidates. The human signal is two-part and still thin. Observationally, higher dietary spermidine intake tracked with lower all-cause mortality in a prospective population study — a real association, but association, confounded by overall diet⁸. Interventionally, a small randomized trial in older adults with subjective cognitive decline tested spermidine supplementation; the pilot hinted at a memory signal⁶, but the larger, better-powered follow-up (SmartAge) did not show a clear cognitive benefit over placebo⁷. So spermidine has a stronger mechanism than most and a suggestive epidemiology, but its best controlled human trial came back essentially negative on the endpoint that mattered. Promising biology, unproven in people. We unpack the full case — autophagy mechanism, animal data, and the negative SmartAge trial — in spermidine for longevity: what the evidence shows.

Resveratrol — 🔴 Hype-led

Resveratrol — the red-wine polyphenol — launched the modern sirtuin-activator hype cycle, and it remains the clearest example of mechanism outrunning humans. It extends lifespan in some lower organisms and improves metabolism in obese mice, but human trials have been consistently underwhelming. Controlled human data show, at best, modest biomarker shifts — small effects on inflammatory and oxidative-stress markers in type-2 diabetes, for instance¹⁰ — and isolated positive findings like improved bone mineral density in postmenopausal women in the RESHAW trial⁹. Those are narrow, surrogate, mixed results, not evidence of slowed aging. Bioavailability is also genuinely poor; oral resveratrol is heavily metabolized before it reaches tissues. For a supplement marketed as a longevity cornerstone, the human ledger is thin and inconsistent — the marketing is the strongest thing about it.

CoQ10 / ubiquinol — 🟢 Reasonable (in the right person)

Coenzyme Q10 is not really an anti-aging compound — it is a mitochondrial electron-transport cofactor — but it earns a green tier because it has something almost nothing else here has: a hard-endpoint randomized trial. In Q-SYMBIO, CoQ10 added to standard therapy in chronic heart-failure patients reduced major adverse cardiovascular events and cardiovascular mortality versus placebo¹¹. That is a real clinical outcome in a defined sick population — not a biomarker, not a mouse. The honest caveats: the benefit is established in heart failure, not in healthy people chasing longevity, and CoQ10 has not been shown to extend lifespan in anyone. As targeted therapy for the right patient (often alongside statins, which lower CoQ10), it's defensible; as a general longevity pill it is unproven.

Omega-3 (EPA/DHA) — 🟢 Reasonable (conditionally)

Marine omega-3s have the largest randomized human evidence base of anything on this list — which is exactly why the picture is more sober than the supplement aisle suggests. In the large VITAL primary-prevention trial, a standard 1 g/day fish-oil dose did not significantly cut the primary cardiovascular or cancer endpoints in the general population¹². But a high-dose, prescription-strength formulation (icosapent ethyl, ~4 g/day) did reduce cardiovascular events in people with elevated triglycerides on statins in REDUCE-IT¹³. The lesson is dose- and population-specific: low-dose fish oil for healthy people is not a proven longevity lever, while high-dose EPA is a genuine cardiovascular intervention for a specific high-risk group. Green tier, with the conditions stated plainly.

Vitamin D — 🟢 Reasonable (to correct deficiency)

Vitamin D is the cleanest example of the deficiency-correction principle. In VITAL — over 25,000 adults randomized — supplemental vitamin D did not reduce cancer or cardiovascular events in a largely replete general population¹⁴. So “vitamin D extends life” is not supported. What is supported is correcting a genuine deficiency: low vitamin D is common, measurable on a blood test, and tied to bone and muscle health. That makes it the rare supplement where the right move is testable — supplement if your level is low, don't assume megadoses buy longevity if it isn't. Reasonable as deficiency correction; not as a blanket longevity drug. A proper longevity biomarker panel will actually measure your level rather than guess.

Fisetin — 🔴 Hype-led (for now)

Fisetin is a flavonoid (strawberries, apples) marketed as a senolytic — a compound that clears senescent “zombie” cells, one of the most exciting aging mechanisms. The mouse data are genuinely striking: fisetin reduced senescent-cell burden and extended health- and lifespan in aged mice¹⁵. But that is a mouse result, and the human senolytic field is still at the pilot-trial stage with no completed, published trial showing fisetin slows aging or improves hard outcomes in people. The dosing regimens sold online (“hit days”) are extrapolated from animal protocols. The mechanism is one of the most promising in longevity science; the human evidence does not yet exist to justify the marketing. Red tier today — a candidate worth watching, not a proven supplement.

Glycine + NAC (GlyNAC) — 🟡 Speculative

GlyNAC combines glycine and N-acetylcysteine to rebuild glutathione, the body's master antioxidant, which declines with age. Unlike most entries here, it has a real (if small) randomized human trial: in older adults, GlyNAC supplementation restored glutathione and improved several aging-associated measures — oxidative stress, mitochondrial markers, inflammation, and some functional readouts — versus placebo¹⁶. That's a more encouraging human signal than NMN or resveratrol can show. The caveats keeping it at yellow: the trials are small, single-group, and not yet replicated at scale, and they measure biomarkers and short-term function, not lifespan. A promising human-data story that needs larger confirmation before the longevity claim is earned.

The scorecard

| Supplement | Mechanism (the hype) | Best human evidence | Tier | |---|---|---|---| | Omega-3 (high-dose EPA) | Anti-inflammatory, lipid-lowering | Reduced CV events in high-risk group (REDUCE-IT) | 🟢 conditional | | Vitamin D | Hormone/bone/immune | No mortality benefit if replete; corrects deficiency | 🟢 for deficiency | | CoQ10 / ubiquinol | Mitochondrial cofactor | Reduced CV mortality in heart failure (Q-SYMBIO) | 🟢 in patients | | NMN / NR | Restore declining NAD+ | Raises NAD+; no outcome data | 🟡 speculative | | Spermidine | Induces autophagy | Mortality association; null cognitive RCT | 🟡 speculative | | GlyNAC | Rebuilds glutathione | Small RCT improved aging biomarkers | 🟡 speculative | | Resveratrol | Sirtuin activator | Modest/mixed biomarker shifts only | 🔴 hype-led | | Fisetin | Senolytic (clears senescent cells) | Mouse-only; human trials pending | 🔴 hype-led |

What this means for your shelf

The pattern is clear once you separate mechanism from proof. The supplements that earn green tiers aren't the futuristic “reverse aging” molecules — they're the boring, measurable ones: correct a real deficiency, or use a high-dose intervention in a defined high-risk group. The exciting compounds (NMN, spermidine, resveratrol, fisetin) sit in yellow and red precisely because their human outcome data don't yet exist, however good the biology looks. None of this is medical advice, and none of these is a substitute for the things with actual lifespan evidence — not smoking, sleep, exercise, and treating blood pressure and metabolic disease.

If you're weighing supplements against prescription longevity approaches, we cover the off-label drugs with the same honesty: metformin for longevity, rapamycin for longevity, and peptides for longevity. And if you'd rather have real physician oversight than self-experiment with a cabinet of capsules, our hub of graded longevity clinics and programs ranks who actually provides it.